The dumping of a controversial Trump administration rule limiting what 340B health centers can charge patients for insulin and EpiPen-type devices took a big step closer to being finalized last week.
Late last week Thursday, the U.S. Health Resources and Services Administration (HRSA) asked the White House Office of Management and Budget (OMB) for clearance to rescind the Trump administration final rule requiring health centers to pass along all their 340B savings on insulin and injectable epinephrine to uninsured or underinsured low-income patients.
The dumping of a controversial Trump administration rule limiting what 340B health centers can charge patients for insulin and EpiPen-type devices took a big step closer to being finalized last week.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
